Skip to content

Author

S. Eldfors

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Sensitivity to ATR-CHK1 pathway inhibition in MDS/AML is enhanced by SRSF2 mutations and reduced by RUNX1 loss.

SRSF2 mutations occur in 5-15% of acute myeloid leukemia (AML) and ~15% of myelodysplastic neoplasms (MDS), are enriched in elderly/secondary AML, and lack mutation-directed therapy. We aimed to identify vulnerabilities in MDS/AML with SRSF2 mutations. Ex vivo drug-sensitivity testing of bone marrow cells from AML pati...

S. Eldfors, Sumit Rai, Vineet Sharma et al. · 0 citations
Open access Aug 2026

TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma

This study integrates ex vivo drug sensitivity profiling, genomics, transcriptomics, and proteomics across 167 CD138+ bone marrow patient samples to characterize TP53-associated vulnerabilities and provides new insights into refining TP53 classification to optimize treatment strategies for high-risk MM.

D. Tsallos, N. Ikonen, Juho J Miettinen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.